EPRX NASDAQ
Credit Risk of going bust: lower than 78% of companies Debt: 0.4% of company value Bonds: none of note held by US funds details ▾
Total debt $1.8M against a stock market value of $452.6M.
Distance to default 9.12 (Merton model): prices to 2026-10-26, balance sheet 2026-06-30, debt counted $920K (short-term plus half of long-term), stock volatility 66.2%; Altman Z'' 12.36. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
Victoria, BC V8R 5G4
CA
Eupraxia Pharmaceuticals Inc., a clinical-stage biotechnology company, focuses on the development of products to address therapeutic areas with unmet medical need. Its proprietary Diffusphere technology optimizes drug delivery for applications with significant unmet medical need. The company's product portfolio includes EP-104IAR, which is in Phase III clinical trial for the treatment of knee osteoarthritis; EP-104GI that is in Phase II clinical trial for treating eosinophilic esophagitis; and EP-104, which is under preclinical studies for the treatment of gastrointestinal tract, such as eosinophilic esophagitis. The company was formerly known as Plaza Capital Partners Inc. and changed its name to Eupraxia Pharmaceuticals Inc. in May 2012. Eupraxia Pharmaceuticals Inc. was incorporated in 2011 and is headquartered in Victoria, Canada.
